Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database
The Oncologist · 10.03.2025 · 30 (3)
DOI: 10.1093/oncolo/oyaf007 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 13.03.2025. Verfasst von Abrahm Levi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Los Angeles, CA, United States. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Liver Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Career Development Award, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Previous research demonstrates longer survival for patients with lung-only metastatic pancreatic adenocarcinoma (mPDAC) compared to liver-only mPDAC. The objective of this study is to understand the survival differences, impact of chemotherapy, and associated genomic features of mPDAC that is isolated to either the liver or lung. Patients and methods Longitudinal clinical outcomes and molecular sequencing data were retrospectively analyzed across 831 patients with PDAC across all stages whose tumors first metastasized to the liver or lung. Survival differences were evaluated using Cox regression. Mutational frequency differences were evaluated using Fisher’s exact test.
Results
Median overall survival (mOS) was shorter in patients with liver-only metastasis (1.3y [1.2-1.4], n = 689) compared to lung-only metastasis (2.1y [1.9-2.5], n = 142) (P = .000000588, HR = 2.00 [1.53-2.63]. Survival differences were observed regardless of choice of 1st-line standard-of-care therapy. For 5-fluorouracil-based therapies, mOS for liver-only mPDAC was 1.4y [1.3-1.6] (n = 211) compared to 2.1y [1.8-3.3] for lung-only mPDAC (n = 175) (P = .008113, HR = 1.75 [1.16-2.65]). For gemcitabine/nab-paclitaxel therapy, mOS for liver-only mPDAC was 1.2y [1.1-1.5] (n = 175) compared to 2.1y [1.6-3.4] for lung-only disease (n = 32) (P = .01863, HR = 1.84 [1.11-3.06]). PDAC tumors with liver-only metastases were modestly enriched (unadjustable P < .05) for: TP53 mutations, MYC amplifications, inactivating CDK2NA alterations, inactivating SMAD alterations, and SWI/SWF pathway mutations. PDAC tumors with lung-only metastases were enriched for: STK11 mutations, CCND1 amplifications, and GNAS alterations.
Conclusion
Patients with lung-only mPDAC demonstrate an improved prognosis relative to those with liver-only mPDAC. Responses to chemotherapy do not explain these differences. Organotropic metastatic tumor diversity is mirrored at the molecular level in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cedars-Sinai Medical Center, Los Angeles, CA, United States.
- Perthera Inc., McLean, VA, United States.
- University of Texas Health Science Center San Antonio, Hematology and Oncology, San Antonio, TX, United States.
- NYU Langone Health, New York, NY, United States.
- University of Arizona College of Medicine, Hematology and Oncology, Tucson, AZ, United States.
- Inova, Fairfax, VA, United States.
ORCID-Profile: Abrahm Levi, Edik Blais, Angela Minasyan, Gillian Gresham, Jennifer W Chuy, Arsen Osipov
Förderung
- Career Development Award
- NCI NIH HHS
- NIH HHS
- American Society of Clinical Oncology
- Conquer Cancer Foundation
- National Institutes of Health
Zitieren
APA
Levi, A., Blais, E., Davelaar, J., Ebia, M. I., Minasyan, A., Nikravesh, N., Gresham, G., Zheng, L., Chuy, J. W., Shroff, R. T., Wadlow, R. C., DeArbeloa, P., Matrisian, L. M., Petricoin, E., Pishvaian, M. J., Gong, J., Hendifar, A. E., & Osipov, A. (2025). Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. The Oncologist, 30(3). https://doi.org/10.1093/oncolo/oyaf007
Vancouver
Levi A, Blais E, Davelaar J, Ebia MI, Minasyan A, Nikravesh N, et al. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. The Oncologist. 2025;30(3). doi:10.1093/oncolo/oyaf007
BibTeX
@article{Levi2025,
author = {Levi, Abrahm and Blais, Edik and Davelaar, John and Ebia, Matthew I and Minasyan, Angela and Nikravesh, Nima and Gresham, Gillian and Zheng, Lei and Chuy, Jennifer W and Shroff, Rachna T and Wadlow, Raymond Couric and DeArbeloa, Patricia and Matrisian, Lynn McCormick and Petricoin, Emmanuel and Pishvaian, Michael J and Gong, Jun and Hendifar, Andrew Eugene and Osipov, Arsen},
title = {Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {3},
doi = {10.1093/oncolo/oyaf007}
}
EUVIMED